Prazepam

w4020 · K-373 · W 4020 · Settima · Centrax · Prazene · Verstran · Trepidan

식별자 및 물리적 특성

CAS No.	2955-38-6
분자식	C19H17ClN2O
평균 분자량	324.8 g/mol
단동위원소 질량	324.1029409 g/mol
SMILES	O=C1CN=C(c2ccccc2)c2cc(Cl)ccc2N1CC1CC1
InChIKey	MWQCHHACWWAQLJ-UHFFFAOYSA-N
PubChem CID	4890
ChEMBL	CHEMBL969
ChEBI	CHEBI:8362
EC No.	220-975-8
DTXSID	DTXSID4021181

화학 및 물리적 성질

XLogP	3.6
극성 표면적	32.7
수소 결합 공여자 수	0
수소 결합 수용자 수	2
회전 가능 결합 수	3
무거운 원자 수	23
형식 전하	0
복잡도	482
LogP(분배 계수)	3.73
용해도	3.99e-03 g/L0.25g을 알코올 R에 녹이고 같은 용매를 가하여 10mL로 한다. 용액은 투명하고(2.2.1) 무색이다(2.2.2, 방법 II).
녹는점	145-146 °C145 - 146 °C145-146°
Physical Description	Solid
Kovats Retention Index	2648265126242630265226762679269426382610265526412650.12620261926562746.92646.32633.22660.52685
Collision Cross Section	174 Å² [M+H]+ [CCS Type: TWMethod: Major Mix IMS/Tof Calibration Kit (Waters)]
끓는 점	538.5±50.0 °C(Predicted)
밀도	1.1660 (rough estimate)
굴절률	1.5790 (estimate)
인화점	11 °C
저장 조건	2-8°C
물리적 상태	고체
pKa(산도 계수)	pKa 2.94 (Uncertain)
색상	흰색에서 황백색까지
용해도	9.095mg/L(25℃)
주요 응용	의약품(소분자)
InChI	1S/C19H17ClN2O/c20-15-8-9-17-16(10-15)19(14-4-2-1-3-5-14)21-11-18(23)22(17)12-13-6-7-13/h1-5,8-10,13H,6-7,11-12H2
InChIKey	MWQCHHACWWAQLJ-UHFFFAOYSA-N
SMILES	Clc1ccc2N(CC3CC3)C(=O)CN=C(c4ccccc4)c2c1
EPA	2H-1,4-Benzodiazepin-2-one, 7-chloro-1-(cyclopropylmethyl)-1,3-dihydro-5-phenyl- (2955-38-6)

안전 및 규제

GHS 분류	This chemical does not meet GHS hazard criteria for 33.3% (1 of 3) of reports.WarningH336 (66.7%): May cause drowsiness or dizziness [Warning Specific target organ toxicity, single exposureNarcotic effects]H361 (66.7%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]H362 (33.3%): May cause harm to breast-fed children [Reproductive toxicity, effects on or via lactation]P203, P260, P261, P263, P264, P270, P271, P280, P304+P340, P318, P319, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 3 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.Reported as not meeting GHS hazard criteria per 1 of 3 reports by companies.There are 2 notifications provided by 2 of 3 reports by companies with hazard statement code(s).Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website.
규제 정보	DEA schedule IV controlled substance2H-1,4-Benzodiazepin-2-one, 7-chloro-1-(cyclopropylmethyl)-1,3-dihydro-5-phenyl-: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.
기타 안전 정보	IMAP assessments - 2H-1,4-Benzodiazepin-2-one, 7-chloro-1-(cyclopropylmethyl)-1,3-dihydro-5-phenyl-: Human health tier I assessmentIMAP assessments - 2H-1,4-Benzodiazepin-2-one, 7-chloro-1-(cyclopropylmethyl)-1,3-dihydro-5-phenyl-: Environment tier I assessment
Hazard Classes and Categories	STOT SE 3 (66.7%)Repr. 2 (66.7%)Lact. (33.3%)
Treatment	General supportive measures should be employed, along with intravenous fluids, and an adequate airway maintained. Hypotension may be combated by the use of norepinephrine or metaraminol. Dialysis is of limited value. Flumazenil (Anexate) is a competitive benzodiazepine receptor antagonist that can be used as an antidote for benzodiazepine overdose. In particular, flumazenil is very effective at reversing the CNS depression associated with benzodiazepines but is less effective at reversing respiratory depression. Its use, however, is controversial as it has numerous contraindications. It is contraindicated in patients who are on long-term benzodiazepines, those who have ingested a substance that lowers the seizure threshold, or in patients who have tachycardia or a history of seizures. As a general rule, medical observation and supportive care are the mainstay of treatment of benzodiazepine overdose. Although benzodiazepines are absorbed by activated charcoal, gastric decontamination with activated charcoal is not beneficial in pure benzodiazepine overdose as the risk of adverse effects often outweigh any potential benefit from the procedure. It is recommended only if benzodiazepines have been taken in combination with other drugs that may benefit from decontamination. Gastric lavage (stomach pumping) or whole bowel irrigation are also not recommended.

용도

개요

Prazepam (Item No. 18358) is an analytical reference material categorized as a benzodiazepine. Prazepam is regulated as a Schedule IV compound in the United States. This product is intended for research and forensic applications.

용도

Sedative-hypnotic.

일반 설명

Prazepam, 7-chloro-1-(cyclopropylmethyl)-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepine-2-one(Verstran), has a long overall half-life. Extensive N-dealkylationoccurs to yield active nordazepam. 3-Hydroxylation ofboth prazepam and nordazepam occurs.